Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study.

Gallo A, Bouchard C, Fortier E, Ducrot C, Rompré PP.

Eur Neuropsychopharmacol. 2014 Sep;24(9):1534-45. doi: 10.1016/j.euroneuro.2014.07.003. Epub 2014 Jul 19.

PMID:
25092427
2.

Animals with a schizophrenia-like phenotype are differentially sensitive to the motivational effects of cannabinoid agonists in conditioned place preference.

Gallo A, Bouchard C, Rompré PP.

Behav Brain Res. 2014 Jul 15;268:202-12. doi: 10.1016/j.bbr.2014.04.020. Epub 2014 Apr 19.

PMID:
24755307
3.

Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Lefever TW, Marusich JA, Antonazzo KR, Wiley JL.

Pharmacol Biochem Behav. 2014 Mar;118:30-5. doi: 10.1016/j.pbb.2014.01.002. Epub 2014 Jan 9.

4.

Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia.

Brady AM, McCallum SE, Glick SD, O'Donnell P.

Psychopharmacology (Berl). 2008 Oct;200(2):205-15. doi: 10.1007/s00213-008-1195-7. Epub 2008 May 26.

5.

Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.

Scherma M, Dessì C, Muntoni AL, Lecca S, Satta V, Luchicchi A, Pistis M, Panlilio LV, Fattore L, Goldberg SR, Fratta W, Fadda P.

Neuropsychopharmacology. 2016 Apr;41(5):1416-26. doi: 10.1038/npp.2015.295. Epub 2015 Sep 21.

6.

CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.

Vlachou S, Nomikos GG, Panagis G.

Psychopharmacology (Berl). 2005 May;179(2):498-508. Epub 2004 Nov 18.

PMID:
15821959
7.

Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.

Vlachou S, Stamatopoulou F, Nomikos GG, Panagis G.

Int J Neuropsychopharmacol. 2008 Nov;11(7):905-23. doi: 10.1017/S1461145708008717. Epub 2008 Apr 1.

8.

The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward.

Flores Á, Maldonado R, Berrendero F.

Biol Psychiatry. 2014 Mar 15;75(6):499-507. doi: 10.1016/j.biopsych.2013.06.012. Epub 2013 Jul 26.

PMID:
23896204
9.

Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder.

Pandolfo P, Vendruscolo LF, Sordi R, Takahashi RN.

Psychopharmacology (Berl). 2009 Aug;205(2):319-26. doi: 10.1007/s00213-009-1542-3. Epub 2009 May 1.

PMID:
19407992
10.

Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.

Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR.

Learn Mem. 2007 Jan 3;14(1-2):63-74. Print 2007 Jan-Feb.

11.

WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation.

Vlachou S, Nomikos GG, Panagis G.

Behav Brain Res. 2003 May 15;141(2):215-22.

PMID:
12742258
12.

Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Spano MS, Fattore L, Cadeddu F, Fratta W, Fadda P.

Psychopharmacology (Berl). 2013 Feb;225(3):531-42. doi: 10.1007/s00213-012-2839-1. Epub 2012 Aug 19.

PMID:
22903392
13.

Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.

Gomes FV, Guimarães FS, Grace AA.

Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu018. doi: 10.1093/ijnp/pyu018.

14.

Cannabinoid self-administration in rats: sex differences and the influence of ovarian function.

Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W.

Br J Pharmacol. 2007 Nov;152(5):795-804. Epub 2007 Sep 24.

15.

Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine.

Polissidis A, Chouliara O, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, Antoniou K.

Behav Brain Res. 2014 Aug 15;270:261-9. doi: 10.1016/j.bbr.2014.05.029. Epub 2014 May 24.

PMID:
24867330
16.

Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats.

Spano MS, Fadda P, Frau R, Fattore L, Fratta W.

Eur Neuropsychopharmacol. 2010 Jan;20(1):25-36. doi: 10.1016/j.euroneuro.2009.09.004.

PMID:
19854030
18.

Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.

Wiley JL, Lowe JA, Balster RL, Martin BR.

J Pharmacol Exp Ther. 1995 Oct;275(1):1-6.

PMID:
7562536
19.
20.

Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.

Gamaleddin I, Wertheim C, Zhu AZ, Coen KM, Vemuri K, Makryannis A, Goldberg SR, Le Foll B.

Addict Biol. 2012 Jan;17(1):47-61. doi: 10.1111/j.1369-1600.2011.00314.x. Epub 2011 Apr 26.

PMID:
21521420

Supplemental Content

Support Center